Skip to main content
Clinical Trials/PACTR202302478939306
PACTR202302478939306Recruiting未知

Possible cardioprotective effect of Nigella Sativa in Type 1 diabetes

Faculty of Mediine Tanta Unversity0 sites60 target enrollmentStarted: January 29, 2023Last updated:

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
6 Year(s) to 12 Year(s) (—)
Sex
All

Inclusion Criteria

  • Type 1 diabetes children and adolescents with age 6-18 years

Exclusion Criteria

  • Clinical evidence of heart failure
  • coronary artery disease
  • systemic hypertension
  • rheumatic fever
  • cardiomyopathy,
  • The use of any medication other than insulin known to affect cardiac function (such as digitalis, angiotensin converting enzyme inhibitor, or ß-blocker)

Investigators

Sponsor
Faculty of Mediine Tanta Unversity

Similar Trials

igella Sativa cardioprotective effect in... | Clinical Trial